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Successful percutaneous mechanical circulatory support (MCS) has been used for
acute stabilization of cardiogenic shock (CS). Improved survival outcomes have
been observed in patients with CS from an acute myocardial infarction (AMI) who
undergo implantation of left ventricular (LV) to ascending aorta rotodynamic
pumps, such as the Impella® device (Abiomed). However, thrombotic events are a
known complication of such devices in poor flow states such as CS. There is
limited evidence regarding the management of patients who develop an LV
thrombus after Impella insertion. Currently, the Sentinel cerebral protection system
(SCPS, Boston Scientific) is the only FDA-approved device for cerebral embolic
protection during transcatheter aortic valve replacement procedures. While the use
of a cerebral embolic protection device (CEPD) has a theoretical benefit, no
current CEPD is approved for use in conjunction with Impella device removal or
other MCS devices. We present a case describing the use of the SCPS during the
removal of the Impella CP device in a patient who developed an LV thrombus after
CS from AMI. Our case highlights a potential role for the expanded use of CEPDs
in similar clinical scenarios.
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Background
Several forms of percutaneous mechanical circulatory support (MCS) exist and
include counterpulsation devices (intra-aortic balloon pumps) and continuous-flow
devices. MCS also includes axial flow devices (Impella [Abiomed]) to advanced
centrifugal flow devices (TandemHeart [LivaNova]) and veno-arterial
extracorporeal membrane oxygenation (V-A ECMO). Device selection is
dependent on several factors, and the potential complications vary from one
device platform to another. The use of Impella is contraindicated in patients with
known left ventricular (LV) thrombus due to the increased risk of
thromboembolism.1 There is an obvious challenge to minimize the risk of embolic
events in patients with LV thrombus that form after Impella implantation. To the
best of our knowledge, literature addressing such a dilemma is scarce. We,
therefore, highlight such a case to share our experience with off-label use of the
Sentinal cerebral protection system (SCPS, Boston Scientific) to minimize embolic
adverse outcomes.

Case Report
A 47-year-old male with no known medical history presented with two days of
dyspnea on exertion and typical chest pain. On arrival, electrocardiogram was
significant for anterior ST-elevation myocardial infarction (Figure 1).

Figure 1. Presenting electrocardiogram shows ST elevation and Q waves in
precordial leads.
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The patient was promptly taken to the cardiac catheterization lab. Emergent
bedside transthoracic echocardiogram (TTE) was significant for severely reduced
LV systolic function with an ejection fraction of < 20% and global hypokinesis
(Figure 2A & B). Left heart catheterization revealed severe two-vessel disease with
subtotal occlusion of the left anterior descending artery and mid-right coronary
artery along with significant left main coronary artery disease. Hemodynamics
(Table 1) were significant for left ventricular end diastolic pressure (LVEDP) at
approximately 50 mmHg, along with elevated filling pressures.

Figure 2. A) This is an Apical 4 chamber view of transthoracic echocardiogram
(TTE) before deployment of the Impella CP. No left ventricular (LV) thrombus is
seen. B) Definity® ultrasound contrast is used in this view and again demonstrates
absence of LV thrombus. C) The tip of the Impella (white arrow) and apical mobile
LV thrombus (red arrow) are identified. D) This is a close up image of the LV
thrombus and tip of Impella. E) This TTE is 48 hours after Impella removal and F)
is the same image with Definity ultrasound contrast. There was a similar finding six
days post-Impella removal prior to discharge.
Table 1. Hemodynamics. Pressures were attained from transthoracic
echocardiogram and right heart catheterization. The cardiac output and index were
calculated by the Fick calculation.
Measure
Left ventricular end diastolic pressure
Right atrial pressure
Right ventricular pressure
Pulmonary arterial systolic pressure/pulmonary
artierial diastolic pressure
Mean pulmonary arterial pressure
Pulmonary capillary wedge pressure
Cardiac output
Cardiac index
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Value Upon Presentation
~50 mmHg
21 mmHg
61/21 mmHg
61/44 mmHg
53 mmHg
42 mmHg
2.39 L/min
1.4 L/min/m2
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Emergent bedside echocardiogram done in the cath lab with DEFINITY®
ultrasound contrast (Lantheus) showed no evidence of LV thrombus. Given the
clinical picture of acute myocardial infarction complicated by CS, the decision was
made to stabilize the patient with MCS, using an Impella CP and to undergo
emergent surgery with coronary artery bypass grafting (CABG). Unfortunately, the
bypass surgery was complicated by circulatory collapse attributed to a protamine
reaction which required emergent cannulation for VA-ECMO with average flow of 3
L/min. 48 hours after Impella implantation and post-CABG, a TTE was significant
for a 2.6 x 0.5 cm size mobile thrombus in the LV apex (Figure 2C, D). Initially
heparin was used for anticoagulation; however, due to progressive
thrombocytopenia and concern for heparin indicued thrombocytopenia (HIT),
anticoagulation therapy was switched to argatroban. The combination of inotropes
and MCS as well as volume optimization with intravenous diuresis, resulted in
clinical improvement. The patient was able to be decannulated from V-A ECMO
after three days. He continued to improve, and after approximately five more days
of Impella support, the device was decreased to lower performance levels using
inotropes and medical management to stabilize him. Given the interval
development of his LV thrombus, and to reduce the risk of any catastrophic
cerebral events in a young patient with no current neurologic deficits, the heart
team (interventional cardiologists, cardiovascular surgeons, heart failure
specialists) decided to remove the Impella in a hybrid operating room setting with
the presence of vascular surgery and interventional cardiology teams. The
multidisciplinary team was needed in part due to the need for immediate femoral
artery hemostasis after Impella is removed. The extraction of the 14 French sheath
while the patient remained on active anticoagulation with argatroban for LV
thrombus and HIT represented a significant risk. We elected to utilize the SCPS to
minimize the risk of cerebral embolization during the Impella removal procedure
(Figure 3).
SCPS was deployed via the right radial artery catherization prior to the Impella
removal, which was performed via a femoral artery cutdown by the vascular
surgeons. Once a femoral artery window with good visualization of the Impella
insertion site and encircled vessel loops were established around the
arteriorotomy, support was decreased from performance level 4 to level 2. The
Impella was then removed and swift hemostasis was achieved with vessel clamps
and interrupted 5-0 prolene suturing. Prior to closure, a thrombus was noted on the
femoral artery posterior wall, which was removed and irrigated. A soft clot was also
found in the Impella blood outlet area (Figure 4). The SCPS was then removed,
and radial artery hemostasis was achieved via a TR band® (Terumo). There were
no post-procedure complications. TTE after Impella removal showed the same,
large (2.6 x 0.5 cm), mobile thrombus attached to the LV apex (Figure 2E, F).
During recovery, the patient did well; no neurologic symptoms or deficits were
noted. The patient experienced complete resolution of his initial presenting
symptom of chest pain. He was discharged on warfarin, insulin for newly
diagnosed diabetes mellitus, and guideline-directed medical therapy for new onset
heart failure and coronary artery disease with cardiology follow-up.
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Figure 3: Sentinel cerebral protection device deployment during Impella removal.
A: Prior to Impella removal with deployment of left carotid artery (black arrow) and
right brachiocephalic artery (white arrow) Sentinel filters were introduced via right
radial access. Distal Impella CP pump near blood outlet area appreciated (red
arrow) and pulmonary artery catheter (*). B: Impella removed via right femoral
artery cutdown with both filters in place (arrows). Subsequent retrieval of left
carotid filter (C) and right brachiocephalic filter (D).

Figure 4: This is the Impella CP (Abiomed) device after removal. A soft clot is
noted in the Impella blood outlet area as pointed out by the arrow.
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Discussion
Our case demonstrates several clinical dilemmas that physicians often face in CS
patients supported by percutaneous MCS. Our patient’s clinical presentation was
significant for CS including severely elevated LVEDP with acute respiratory failure
and pulmonary edema from his acute MI (Table 1). The Impella CP (Performace
level 4 and 2 L/min flow) was sufficient to unload his severely hypokinetic LV and
provide adequate hemodynamic support until revascularization with CABG.
However, due to circulatory collapse from protamine use during CABG, our patient
required emergent extracorporeal life support with V-A ECMO. This event resulted
in further myocardial stunning in an already poorly contracting LV. The resultant
turbulent blood flow within the LV cavity and potential stasis significantly increased
the risk of developing an intra-cardiac thrombus.2 Despite adequate
anticoagulation, the risk of intra- or extra-cardiac thrombus formation is reported to
be 3.9% in patients with impaired LV function who undergo femoral V-A ECMO
with LV unloading.3
Concomitant use of V-A ECMO and Impella is an often-used technique to vent the
failing LV. By offloading the LV, the Impella device lowers LVEDP in the setting of
increased afterload due to the presence of the V-A ECMO outflow catheter in the
aorta.2 Our patient required full circulatory support with V-A ECMO due to
vasodilatory, distributive shock after protamine during CABG, which resulted in
circulatory collapse. On the platform of V-A ECMO, the addition of an Impella
device to reduce ventricular loading results in improved survival and recovery of
ventricular performance in the setting of CS.2 However, there is an increased risk
of complications related to the thrombogenic nature of MCS devices in the LV. The
risk of cerebrovascular accidents in such patients are reported to be as high as
10%.2,4 In the case of our patient, several factors, such as decreased flow due to
CS, a severely akinetic apical segment, and multiple MCS devices, led to an
overall increased risk for thrombotic events. Management strategies for patients
with femoral V-A ECMO support and severely impaired LV function must be
reassessed to avoid insufficient LV unloading at an early stage of ECMO therapy.
Adjusting the flow rate of ECMO and Impella, as well as ionotropic support and
diuresis should be considered in patients with insufficient unloading of the LV to
prevent intra-cardiac thrombus formation and reduce LV distention. Despite all
these measures, our patient had thrombotic complications.
The SCPS is FDA-approved and indicated for use during TAVR procedures to
protect against embolic events.5,6 Herein, we demonstrate the application of this
device in a relatively unique clinical dilemma. We understand its use in our
scenario may not eradicate cerebral embolic events; however, we believe it
provided an overall clinical benefit to our patient compared to the potential
ramifications of Impella removal without SCPS. Therefore, the use of SPCS during
MCS removal, such as Impella, in patients with an intra-cardiac thrombus may be
a future indication for this device. Further investigation is necessary to understand
the applicability to the general population prior to its widespread use.
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Conclusion
As the utilization of percutaneous MCS continues to increase, related
complications will need to be carefully monitored. A multi-disciplinary approach,
including interventional cardiologists, heart failure subspecialists and
cardiovascular surgeons, will be crucial in managing such events. Current
conventional options, such as the SCPS to prevent cerebral embolic events, as
well as other emerging therapies will need to be adapted to address these issues
going forward.
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